Having just completed a private placement of $45m, adding to its healthy cash reserves, Norwegian biotech Nykode Therapeutics AS is carrying on with plans to list stateside while advancing its cervical cancer vaccine towards potentially registrational trials.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?